The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
08-Jun-25
Pending
Undisclosed
Target:
Pinnacle Towers / KKR
Acquiror:
BCI
Sole financial advisor to KKR on British Columbia Investment Management Corporation’s (“BCI”) investment into Pinnacle Towers, the largest independent TowerCo in the Philippines
17-Mar-25
Pending
$535 million
Target:
Notified
Acquiror:
Equiniti Group (a Siris Capital Group portfolio company)
Advising Equiniti Group, a Siris Capital Group portfolio company, on the acquisition of the Notified, a wholly owned subsidiary of West Technology Group., an Apollo Global Management portfolio company
11-Feb-25
$320 million (AUD value)
Target:
Pacific Smiles Group
Acquiror:
Genesis Capital
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
12-Dec-24
$460 million
Target:
Brigit
Acquiror:
Upbound Group
Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company
13-Nov-24
Pending
$12.1 billion
Target:
Blue Owl Technology Finance Corp. II (“OTF II”)
Acquiror:
Blue Owl Technology Finance Corp. (“OTF”)
Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
30-Sep-24
Undisclosed
Target:
Golub Capital LLC
Acquiror:
Mizuho Bank, Ltd.
Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
06-May-24
Pending
Undisclosed
Target:
Veen Bosch & Keuning
Acquiror:
Simon & Schuster
Advising Veen Bosch & Keuning, the largest book publisher in the Netherlands, on its sale to Simon & Schuster, one of the world’s preeminent publishing houses
05-Apr-24
$820 million (AUD)
Target:
illion Australia Pty Ltd
Acquiror:
Experian Plc
Advising Experian Plc, the world’s leading global information services company, on the acquisition of illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
21-Dec-23
Undisclosed
Target:
Exit of Homesafe Equity Release Joint Venture
Acquiror:
Athy Pty Ltd
Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture
18-Sep-23
Pending
Undisclosed
Target:
Central nervous system (CNS) portfolio from Sanofi
Acquiror:
Pharmanovia
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
21-Jul-23
Undisclosed
Target:
Synfonium / Qwant / Shadow
Acquiror:
Caisse des Dépôts et Consignations (CDC) / Banque des Territoires
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
26-Jun-23
$583 million
Target:
Mandala Multifinance
Acquiror:
MUFG and Adira Finance
Advised JG Motor and certain other shareholders on the sale of Mandala Multifinance, a leading consumer finance company listed in Indonesia to MUFG and Adira Finance
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
10-Feb-23
Pending
$415 million
Target:
Gaming Services Division of Global Payments
Acquiror:
Parthenon Capital
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies